<?xml version="1.0" encoding="UTF-8"?>
<p>Idiopathic pulmonary fibrosis differs from COVID-19-related pulmonary fibrosis however, it is worth searching for a solution to this problem within these drug groups or therapeutic options. The currently ongoing clinical trials evaluating a wide range of potentially beneficial strategies for the prevention and treatment of pulmonary fibrosis associated with COVID-19 have been summarized in 
 <xref rid="jcm-09-01917-t003" ref-type="table">Table 3</xref>.
</p>
